Melanoma
Conference Coverage
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest...
Conference Coverage
Neoadjuvant immunotherapy combo produces high response rate in melanoma
News
Vaccine regimen boosts immune response in malignant melanoma
Adding a hematopoietic cytokine to a dendritic cell-targeted vaccine improved responses.
News
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
Conference Coverage
Lower BP and better tumor control with drug combo?
Article
Are oncologists ready to confront a second wave of COVID-19?
News
Survey of Mohs surgeons highlights its use in invasive melanoma
“Mohs surgeons who previously treated MIS with MMS may be increasingly doing so and/or expanding their scope of treatment to include invasive...
Opinion
The scope of under- and overtreatment in older adults with cancer
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
Article
COVID-19 prompts ‘democratization’ of cancer trials
Dr. Alan Lyss reviews a panel discussion about how COVID-19 has affected cancer research.